June 2026 in “World Journal of Clinical Pediatrics” Early diagnosis and tailored treatment improve outcomes for non-nutritional rickets.
May 2026 in “Frontiers in Immunology” Bimekizumab effectively treats scalp cellulitis and improves quality of life.
August 2009 in “Australian Prescriber” Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.
Belimumab effectively controls SLE disease activity and reduces steroid use.
70 citations
,
February 2018 in “Seminars in Arthritis and Rheumatism” Belimumab reduces disease activity, steroid use, and flares in lupus patients.
3 citations
,
July 2022 in “European Journal of Dermatology” Brodalumab is more effective than ustekinumab for treating psoriasis.
May 2025 in “The Journal of Rheumatology” Anti-CD19 therapy may help treat SLE and NMOSD.
May 2020 in “The journal of investigative dermatology/Journal of investigative dermatology” BIVV009 is a safe treatment for bullous pemphigoid that reduces C3 deposition without harmful side effects.
September 2024 in “Cureus” Guselkumab effectively treats skin reactions caused by adalimumab in certain conditions.
October 2025 in “Australasian Journal of Dermatology” Bimekizumab effectively treated a man's chronic beard hair loss.
1 citations
,
June 2020 in “Annals of the rheumatic diseases” Most patients successfully switched from the original adalimumab to a biosimilar with few reverting due to reduced effectiveness or side effects.
May 2022 in “Journal of Neurology Neurosurgery & Psychiatry” Erenumab significantly reduced migraine days or severity in most patients after 3 months.
1 citations
,
July 2021 in “Acta dermatovenerologica Croatica” Adalimumab significantly improved symptoms and quality of life in two patients with Hidradenitis Suppurativa.
Patients with acute and subacute skin lupus respond faster to belimumab than those with chronic skin lupus.
May 2026 in “SKIN The Journal of Cutaneous Medicine” Bimekizumab can improve scarring alopecia in severe psoriasis.
7 citations
,
December 2022 in “Skin Appendage Disorders” Certolizumab effectively treats psoriasis and psoriatic arthritis with fewer side effects than adalimumab.
2 citations
,
September 2024 in “Internal Medicine Journal” Upadacitinib helped regrow hair and maintain ulcerative colitis remission.
November 2025 in “Reumatismo” The choice between belimumab and anifrolumab depends on the specific symptoms of the patient's lupus.
September 2025 in “Arthritis Research & Therapy” BMS-470539 reduces skin fibrosis and inflammation.
August 2025 in “JEADV Clinical Practice” Dupilumab successfully treated a woman's alopecia areata and bullous pemphigoid, leading to full hair regrowth and symptom resolution.
November 2025 in “DOAJ (DOAJ: Directory of Open Access Journals)” The choice between belimumab and anifrolumab for treating lupus depends on the patient's specific symptoms.
November 2024 in “Journal of Investigative Dermatology” Bimekizumab quickly improves psoriasis symptoms and skin at the molecular level.
Belimumab may cause hair loss in lupus patients.
156 citations
,
August 2014 in “Cochrane library” Budesonide is not effective for maintaining remission in Crohn's disease beyond three months.
13 citations
,
January 2021 in “The American journal of gastroenterology” Sirolimus effectively reduces lesions and improves quality of life in Blue Rubber Bleb Nevus Syndrome with manageable side effects.
37 citations
,
October 2014 in “JAMA dermatology” A woman with severe hair loss was successfully treated with the drug adalimumab.
October 2024 in “American Journal of Case Reports” Baricitinib improved hair loss and arthritis in a lupus patient.
Adalimumab significantly improved Hidradenitis Suppurativa and quality of life in two patients.
1 citations
,
April 2016 in “Journal of The American Academy of Dermatology” Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.
July 2022 in “European Journal of Dermatology” Brodalumab is more effective than ustekinumab in treating psoriasis.